MUMBAI, India, June 13, 2011 /PRNewswire/ — Pharma Major Lupin
Limited announced today that its U.S. subsidiary, Lupin
Pharmaceutical Inc. was presented with the 2011 DIANA Award by the
Healthcare Distribution Management Association (HDMA) for the Best
Overall Generic Product Manufacturer among those companies with
sales of up to $100 million in the Healthcare Distributor
market.
The DIANA award winners are selected by HDMA Distributor members
to recognize companies that continually foster strong trading
partner relationships with the Association’s primary distributor
members by creating exceptional business practices that advance
trade relations and benefit the entire US healthcare supply chain.
Commenting on the award, Paul McGarty, President of Lupin
Pharmaceuticals Inc. said, “We are very pleased and honored with
the recognition that Lupin received from the HDMA.” Mr.
McGarty added, “This is very exciting when we consider that Lupin
launched its Generics Rx division in December 2005 and this award
is a reflection of our unwavering commitment to excellence and
collaborative relationships with our trading partners.”
About Lupin Limited
Headquartered in Mumbai, India, Lupin Limited is an innovation
led transnational pharmaceutical company producing a wide range of
quality, affordable generic and branded formulations and APIs. The
Company today has significant presence in Cardiovasculars (prils
and statins), Diabetology, Asthma, Pediatrics, CNS, GI,
Anti-Infectives and NSAIDs in addition to holding global leadership
positions in the Anti-TB and Cephalosporins space.
Today, Lupin is the 5th largest and the fastest growing Top 5
generics player in the U.S. (by prescriptions), the only Asian
company to achieve that distinction. The company is also the
fastest growing top 10 pharmaceutical players in India, Japan and
South Africa. (IMS)
For the financial year ended March 2011, Lupin’s
Consolidate
‘/>”/>